FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma – OncLive
|
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
OncLive The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according to Celgene Corporation and bluebird bio, the companies developing the anti–B-cell maturation antigen … |
